megestrol / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 138 Diseases   26 Trials   26 Trials   791 News 


12345678910»
  • ||||||||||  megestrol / Generic mfg.
    Clinical guideline, Journal:  SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023). (Pubmed Central) -  Oct 11, 2024   
    While pharmacological agents like megestrol acetate may be considered, their use requires careful evaluation of potential risks. At its core, this review underscores the imperative for a holistic and personalized approach to managing CACS, integrating nutritional interventions and pharmacological strategies based on a nuanced understanding of patient's condition.
  • ||||||||||  megestrol / Generic mfg.
    COMPLETE REMISSION OF ADVANCED LOW-GRADE ENDOMETRIAL STROMAL SARCOMA AFTER ENDOCRINE THERAPY: A CASE REPORT () -  Oct 11, 2024 - Abstract #ASCOMOS2024ASCOMOS_250;    
    Oral Megestrol acetate 160 mg per day was prescribed...CONCLUSION We report a case of rapidly progressing low-grade ESS treated with first line endocrine therapy in which demonstrated a complete remission. Multi-analysis from a large group of patients is needed to emphasize the role of endocrine therapy in low-grade ESS.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk
    Trial completion date, Trial primary completion date:  Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia (clinicaltrials.gov) -  Sep 26, 2024   
    P2/3,  N=0, Withdrawn, 
    Multi-analysis from a large group of patients is needed to emphasize the role of endocrine therapy in low-grade ESS. Trial completion date: Nov 2024 --> Nov 2026 | Trial primary completion date: Nov 2022 --> Nov 2025
  • ||||||||||  Trulicity (dulaglutide) / Eli Lilly
    Journal:  Megesterol acetate as an overlooked cause of hyperglycemia in end-stage renal disease: A case of polypharmacy. (Pubmed Central) -  Sep 15, 2024   
    It is also important for healthcare professionals to be cognizant of medications that may exhibit glucocorticoid properties, which can cause hyperglycemia. Including a clinical pharmacist in the care team can assist with medication reconciliation, screening for drug interactions and polypharmacy, and optimizing chronic disease management.
  • ||||||||||  megestrol / Generic mfg.
    METASTATIC ENDOMETRIOID ADENOCARCINOMA IN THE LUNGS 14 YEARS AFTER HYSTERECTOMY FOR NONCANCEROUS ETIOLOGY (Convention Center Exhibit Hall: Rapid Fire Area 4A) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_6687;    
    Our patient was incidentally found to have diffuse pulmonary nodules and was ultimately diagnosed with metastatic endometrioid adenocarcinoma despite undergoing a hysterectomy for non-cancerous reasons over 14 years prior. A thorough evaluation prior to organ donation or transplantation is crucial to optimizing outcomes.
  • ||||||||||  Visanne (dienogest) / Mochida, Bayer
    Review, Journal:  Antitumor progestins activity: Cytostatic effect and immune response. (Pubmed Central) -  Aug 17, 2024   
    Such progestins as dienogest, megestrol acetate and levonorgestrel increase the activity of NK-cells, which play a major role in the body's fight against tumor cells. The use of existing progestins and the development of new drugs with gestagenic activity may hold promise in oncotherapy.
  • ||||||||||  megestrol / Generic mfg.
    Trial primary completion date:  Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma (clinicaltrials.gov) -  Aug 12, 2024   
    P2/3,  N=89, Recruiting, 
    The use of existing progestins and the development of new drugs with gestagenic activity may hold promise in oncotherapy. Trial primary completion date: Feb 2024 --> Feb 2025
  • ||||||||||  Zulresso (brexanolone) / Sage Therapeutics, Zurzuvae (zuranolone) / Sage Therapeutics, Biogen
    Review, Journal:  Supportive care of female hormones in brain health: what and how? (Pubmed Central) -  Aug 8, 2024   
    However, the potential risks and uncertainties associated with hormone therapy treatment modalities can be daunting for both patients and medical professionals. This review aims to offer a comprehensive understanding of the non-reproductive functions and mechanisms of female hormones in brain health.
  • ||||||||||  tamoxifen / Generic mfg., megestrol / Generic mfg.
    MILIARY NODULES: WHEN YOU HEAR HOOFS BUT IT'S A ZEBRA (Convention Center 256) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_536;    
    Patient was referred back to her oncologist who started her on alternating treatment of Tamoxifen and Megestrol. In conclusion, this case highlights the importance of maintaining pulmonary benign metastasizing leiomyoma as a differential for miliary nodules in the appropriate patient population of not only reproductive age females - even as the presenting symptom [3] - but also post-menopausal women with a prior history of leiomyoma.
  • ||||||||||  megestrol / Generic mfg.
    Trial primary completion date:  Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia (clinicaltrials.gov) -  Jul 19, 2024   
    P2/3,  N=172, Recruiting, 
    The patients without an initial response to progestins and whose AEH progressed to endometrial carcinoma had good prognoses. Trial primary completion date: Feb 2024 --> Feb 2025
  • ||||||||||  progesterone / Generic mfg., megestrol / Generic mfg.
    Journal:  Correlation between steroid receptor expression and response to progestational therapy in patients with atypical endometrial hyperplasia or cancer. (Pubmed Central) -  May 3, 2024   
    Retrospective cohort study collected data for patients with AEH or EMCA who had an endometrial sample after receiving conservative therapy utilizing either Megestrol acetate or Levonorgestrel Intrauterine device (IUD). Immunohistochemistry (IHC) was performed on pre- and post- treatment biopsy samples to assess androgen receptor (AR), estrogen receptor (ER), and progesterone receptor (PR) expression...Patients who successfully responded to the treatment demonstrated a significantly greater decrease in IHC scores after the treatment compared to those who did not respond (p
  • ||||||||||  metformin / Generic mfg.
    Clinical, Review, Journal:  Metformin for endometrial hyperplasia. (Pubmed Central) -  May 2, 2024   
    Review authors found insufficient evidence to either support or refute the use of metformin, specifically megestrol acetate, given alone or in combination with standard therapy, for the treatment of women with endometrial hyperplasia. Robustly designed and adequately powered randomised controlled trials, yielding long-term outcome data are still needed to address this clinical question.
  • ||||||||||  tamoxifen / Generic mfg., megestrol / Generic mfg.
    Treatment modalities for advanced solid pseudopapillary tumor of the pancreas. () -  Apr 24, 2024 - Abstract #ASCO2024ASCO_5240;    
    Cytoreductive surgery may improve survival. Simultaneously enriching Wnt and progesterone receptor signaling pathway may partially explain the low aggressive ability of SPT and their unbalance may lead to the aggressive behavior of SPT.
  • ||||||||||  Kremezin (AST-120) / Mitsubishi Tanabe
    Journal:  Pharmacologic therapeutics in sarcopenia with chronic kidney disease. (Pubmed Central) -  Feb 23, 2024   
    AST-120 prevented IS and PCA tissue accumulation, ameliorated muscle atrophy, improved exercise capacity and mitochondrial biogenesis, restored epithelial tight junction proteins, and reduced plasma endotoxin levels and markers of oxidative stress and inflammation. In a human study, the addition of AST-120 to standard treatment had modest beneficial effects on gait speed change and quality of life.
  • ||||||||||  Adlumiz (anamorelin) / Helsinn, Ono Pharma
    Review, Journal:  Addressing cancer anorexia-cachexia in older patients: Potential therapeutic strategies and molecular pathways. (Pubmed Central) -  Feb 5, 2024   
    This review aims to elucidate the molecular mechanisms underpinning CC, with a particular focus on the role of anorexia in exacerbating muscle wasting, and to propose pharmacological and non-pharmacological strategies to mitigate this syndrome, particularly emphasising the needs of an older demographic. Future research targeting CC should focus on refining appetite-stimulating drugs with fewer side-effects, specifically catering to the needs of older patients, and investigating nutritional factors that can either enhance appetite or minimise suppression of appetite in individuals with CC, especially within this vulnerable group.
  • ||||||||||  megestrol / Generic mfg., rosuvastatin / Generic mfg.
    Trial completion date, Trial primary completion date:  Megestrol Acetate Plus Rosuvastatin in Young Women With Early Endometrial Carcinoma (clinicaltrials.gov) -  Jan 29, 2024   
    P2,  N=48, Recruiting, 
    Recruiting --> Completed | Trial completion date: Nov 2022 --> Oct 2023 Trial completion date: Aug 2023 --> Aug 2025 | Trial primary completion date: Aug 2023 --> Aug 2025
  • ||||||||||  megestrol / Generic mfg.
    Molecular Classification In Patient With Endometrial Cancer Undergoing Fertility Preserving Approach. (Poster area) -  Jan 18, 2024 - Abstract #ESGO2024ESGO_930;    
    Squamous metaplasia was detected in 6 cases.The type of progesterone used in the treatment was megestrol asetat in 11 (68%) patients and megestrol asetat+LNG IUD in 5 cases...There is a need for further study on other molecular features that can predict prognosis and treatment response in the NSMP group. Response rates to progesterone treatment in cases with squamous metaplasia should also be evaluated in larger series.
  • ||||||||||  megestrol / Generic mfg.
    Trial completion date, Trial primary completion date:  Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer (clinicaltrials.gov) -  Jan 9, 2024   
    P2,  N=50, Recruiting, 
    Response rates to progesterone treatment in cases with squamous metaplasia should also be evaluated in larger series. Trial completion date: May 2024 --> Nov 2024 | Trial primary completion date: May 2024 --> Nov 2024